@article{JTD10071,
author = {Dario Buccheri and Davide Piraino and Giuseppe Andolina and Bernardo Cortese},
title = {Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment},
journal = {Journal of Thoracic Disease},
volume = {8},
number = {10},
year = {2016},
keywords = {},
abstract = {The lumen diameter reduction after percutaneous coronary intervention (PCI) is well known as “restenosis”. This phenomenon is due to vessel remodeling/recoil in case of no-stent strategy or, in case of stent employ, “neointimal proliferation” that consists in an excessive tissue proliferation in the luminal surface of the stent otherwise by a further new-occurring atherosclerotic process called “neoatherosclerosis”. The exact incidence of in-stent restenosis (ISR) is not easy to determine caused by different clinical, angiographic and operative factors. In the pre-stent era the occurrence of restenosis ranged between 32–55% of all angioplasties, and drop to successively 17–41% in the bare metal stents (BMS) era. The advent of drug-eluting stent (DES), especially 2nd generation, and drug-coated balloon (DCB) further reduce restenosis rate until },
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/10071}
}